# A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

> **NCT01562899** · PHASE1,PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- BRAF Mutated Melanoma

## Interventions

- **DRUG:** MEK162
- **DRUG:** AMG 479

## Key facts

- **NCT ID:** NCT01562899
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-08-27
- **Primary completion:** 2015-04-01
- **Final completion:** 2015-04-01
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** Study was withdrawn due to scientific and business considerations.
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562899, "A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01562899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*